Homebiopharmaceutical

biopharmaceutical

AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections

AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections

January 4, 2021

Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO(TM) as the Brand Name for MAT9001

January 4, 2021

EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics

EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics

January 3, 2021

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important January 26 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – FBIO

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important January 26 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – FBIO

January 2, 2021

MERGER INVESTIGATION ALERT: Halper Sadeh LLP Encourages NK, PRGX, CBLI, and IPHI Shareholders to Contact the Firm

MERGER INVESTIGATION ALERT: Halper Sadeh LLP Encourages NK, PRGX, CBLI, and IPHI Shareholders to Contact the Firm

January 2, 2021

Aravive Announces Board Member Transition to Advisory Role

Aravive Announces Board Member Transition to Advisory Role

December 31, 2020

FBIO LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Fortress Biotech, Inc. Investors with Losses over $100K to Seek Counsel Before Important January 26 Deadline in Securities Class Action – FBIO

FBIO LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Fortress Biotech, Inc. Investors with Losses over $100K to Seek Counsel Before Important January 26 Deadline in Securities Class Action – FBIO

December 31, 2020

Anavex Life Sciences (AVXL) Upgraded to Buy: Here’s Why

Anavex Life Sciences (AVXL) Upgraded to Buy: Here’s Why

December 31, 2020

FBIO Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Fortress Biotech, Inc. Investors of Class Action and Lead Plaintiff Deadline: January 26, 2021

FBIO Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Fortress Biotech, Inc. Investors of Class Action and Lead Plaintiff Deadline: January 26, 2021

December 31, 2020

Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B

Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B

December 31, 2020

« 1 … 535 536 537 538 539 … 558 »